Publications by authors named "Toshinori Katsurabara"
Background And Aim: E6011 is a humanized monoclonal antibody targeting fractalkine (FKN), a CX3C chemokine, which regulates leukocyte trafficking during inflammation. We evaluated the safety and pharmacokinetic profile of E6011 in patients with Crohn's disease (CD) and also performed preliminary pharmacodynamic (PD) and efficacy assessments.
Methods: This study included a 12-week multiple ascending dose (MAD) phase (2, 5, 10, and 15 mg/kg intravenously every 2 weeks, n = 6, 8, 7, and 7, respectively) and a 40-week Extension phase (n = 12) at the same dose as the MAD phase.
Article Synopsis
- E6011 is a new monoclonal antibody being tested for conditions like Crohn's disease, rheumatoid arthritis, and primary biliary cholangitis, evaluated through a study with 64 healthy Japanese men.
- The study was designed as a randomized, double-blind, placebo-controlled trial where varying doses of E6011 were administered intravenously to assess safety and efficacy related to its target, chemokine fractalkine (FKN).
- Results indicated that E6011 was safe and well-tolerated, with evidence of its effectiveness in increasing serum FKN levels and informing future dosing strategies for patient studies.
Molecular design of novel spin-labeled nucleosides directly attached base moiety.
Nucleic Acids Symp Ser (Oxf)
July 2007
N-tert-Butylaminoxyl nucleosides (1 and 2) were synthesized starting from 6-chloropurine derivative (3). These compounds are expected as a new tool to elucidate structure of DNA. Their properties and pH-dependent change of EPR spectra were studied.
View Article and Find Full Text PDF